Technologies
PDF


WARF: P06269US

Novel Subtype of Botulinum Toxin For Pharmaceutical Use


INVENTORS -

Eric Johnson, Kristin Marshall, Sabine Pellett, Marite Bradshaw

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing a novel botulinum neurotoxin type A formulation useful for patients resistant to BOTOX.
OVERVIEWClostridium botulinum produces botulinum neurotoxin (BoNT), which can cause debilitating disease but also is used to treat disorders like chronic headache, spastic muscles and strabismus.

The bacteria produce seven distinguishable serotypes of BoNT, designated A-G. Commercially available pharmaceuticals and the cosmetic agent BOTOX are derived from type A. While the most widely used, type A is immunogenic, meaning patients become resistant to it after repeated use.
THE INVENTIONUW–Madison researchers have isolated a novel plasmid found in a C. botulinum type A strain that is not neutralized by antibodies. The plasmid encodes genes for subtypes BoNT/A3 or BoNT/A4 and BoNT/B. The neurotoxins can be purified and formulated into pharmaceuticals or vaccines.
APPLICATIONS
  • Producing purified botulinum neurotoxin for research, therapy and cosmetics
KEY BENEFITS
  • Not neutralized by the immune system
  • Could prolong the effectiveness of BOTOX and other treatments
STAGE OF DEVELOPMENTThe researchers have purified botulinum neurotoxin from subtypes A3 and A4.
Contact Information
For current licensing status, please contact Andy DeTienne at adetienne@warf.org or 608-960-9857.
The WARF Advantage

WARF: A Leader in Technology Transfer Since 1925
Since its founding as a private, nonprofit affiliate of the University of Wisconsin–Madison, WARF has provided patent and licensing services to UW–Madison and worked with commercial partners to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.

The University of Wisconsin and WARF –
A Single Location to Accelerate Translational Development of New Drugs

UW–Madison has the integrative capabilities to complete many key components of the drug development cycle, from discovery through clinical trials. As one of the top research universities in the world, and one of the two best-funded universities for research in the country, UW–Madison offers state-of-the-art facilities unmatched by most public universities.

These include the Small Molecule Screening Facility at the UW Comprehensive Cancer Center; the Zeeh Pharmaceutical Experiment Station, which provides consulting and laboratory services for developing formulations and studying solubility, stability and more; the Waisman Clinical Biomanufacturing Facility; the Wisconsin Institute for Medical Research, which provides UW–Madison with a complete translational research facility; and the innovative, interdisciplinary Wisconsin Institutes for Discovery, home to the private, nonprofit Morgridge Institute for Research and its public twin, WID, part of the university's graduate school. The highly qualified experts at these facilities are ready to work with you to create a library of candidates for drug development.